Biocon earns USFDA nod for Liraglutide injection, boosting its diabetes drug portfolio. Explore investment opportunities now!

While the injectable retains convenience advantages in dosing frequency, the pill addresses needle aversion and may facilitate broader uptake in primary care settings.

JSKN021 is a “2-in-1” dual payload bispecific ADC targeting EGFR and HER3. By leveraging glycan-specific conjugation technology, it precisely and quantitatively links two different cytotoxic payloads ...

Event-driven primary disease-free survival ('DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ('PDAC”) is anticipated in 1H 2026Fewer ...

Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee ...

Since the publication of a decree a year ago, more and more traditional healthcare facilities in France have been encouraged to choose at-home chemotherapy solutions.